In patients with breast cancer, the outcome of prediction and treatment response depends on immunohistochemical (IHC) markers such as ER, PR, and HER-2, as well as standard clinicopathologic features such as tumor size, grade, and lymph node involvement, which often exhibit potentially different outcomes due to other clinical manifestations and molecular characteristics. The gene discussed is ESR1; the disease is breast cancer.